Cholesterol and Alzheimer's disease: A still poorly understood correlation

IUBMB Life

Volumn 64, Issue 12, 2012, Pages 931-935

  Ricciarelli, Roberta ^a   Canepa, Elisa ^a   Marengo, Barbara ^a   Marinari, Umberto M ^a   Poli, Giuseppe ^b   Pronzato, Maria A ^a   Domenicotti, Cinzia ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Alzheimer's disease; amyloid beta; amyloid precursor protein; apolipoprotein E; cholesterol; statins

Indexed keywords

ABC TRANSPORTER A1; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BLOOD BRAIN BARRIER; CELL MEMBRANE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CHOLESTEROL INTAKE; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; COGNITIVE DEFECT; CYTOTOXICITY; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENETIC RISK; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC HEART DISEASE; LEARNING DISORDER; LIPID RAFT; LIPOPHILICITY; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NONHUMAN; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTICHOLESTEREMIC AGENTS; CEREBRAL CORTEX; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; RETROSPECTIVE STUDIES;

ANIMALIA;

EID: 84870199964     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1091     Document Type: Review

References (65)

1. Glenner, G. G., and, Wong, C. W., (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890. (Pubitemid 14104991)
2. Haass, C., and, Selkoe, D. J., (1993) Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 75, 1039-1042.
3. De Strooper, B., and, Annaert, W., (2000) Proteolytic processing and cell biological functions of the amyloid precursor protein. J. Cell. Sci. 113 (pt 11), 1857-1870. (Pubitemid 30386490)
4. De Strooper, B., (2003) Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 38, 9-12. (Pubitemid 36423348)
5. Morell, P., and, Jurevics, H., (1996) Origin of cholesterol in myelin. Neurochem. Res. 21, 463-470. (Pubitemid 26159264)
6. Poirier, J., Baccichet, A., Dea, D., and, Gauthier, S., (1993) Cholestero l synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience 55, 81-90. (Pubitemid 23194987)
7. Pfrieger, F. W., (2003) Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? Bioessays 25, 72-78. (Pubitemid 36093328)
8. Mulder, M., (2009) Sterols in the central nervous system. Curr. Opin. Clin. Nutr. Metab. Care 12, 152-158.
9. Bjorkhem, I., and, Meaney, S., (2004) Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 24, 806-815. (Pubitemid 38620856)
10. Sun, Y., Yao, J., Kim, T. W., and, Tall, A. R., (2003) Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J. Biol. Chem. 278, 27688-27694. (Pubitemid 36899957)
11. Koldamova, R., Staufenbiel, M., and, Lefterov, I., (2005) Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 280, 43224-43235. (Pubitemid 43049289)
12. Wahrle, S. E., Jiang, H., Parsadanian, M., Hartman, R. E., Bales, K. R., et al. (2005) Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280, 43236-43242. (Pubitemid 43049290)
13. Grimm, M. O., Grimm, H. S., Patzold, A. J., Zinser, E. G., Halonen, R., et al. (2005) Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 7, 1118-1123.
14. Canepa, E., Borghi, R., Vina, J., Traverso, N., Gambini, J., et al. (2011) Cholesterol and amyloid-beta: evidence for a cross-talk between astrocytes and neuronal cells. J. Alzheimers Dis. 25, 645-653.
15. Ehehalt, R., Keller, P., Haass, C., Thiele, C., and, Simons, K., (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell. Biol. 160, 113-123. (Pubitemid 36091721)
16. Tun, H., Marlow, L., Pinnix, I., Kinsey, R., and, Sambamurti, K., (2002) Lipid rafts play an important role in A beta biogenesis by regulating the beta-secretase pathway. J. Mol. Neurosci. 19, 31-35. (Pubitemid 35013331)
17. Wahrle, S., Das, P., Nyborg, A. C., McLendon, C., Shoji, M., et al. (2002) Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 9, 11-23. (Pubitemid 34174561)
18. Puglielli, L., Konopka, G., Pack-Chung, E., Ingano, L. A., Berezovska, O., et al. (2001) Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3, 905-912. (Pubitemid 32952255)
19. Hutter-Paier, B., Huttunen, H. J., Puglielli, L., Eckman, C. B., Kim, D. Y., et al. (2004) The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron 44, 227-238. (Pubitemid 39346248)
20. Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C. G., et al. (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl. Acad. Sci. USA 95, 6460-6464. (Pubitemid 28249035)
21. Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., et al. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98, 5856-5861. (Pubitemid 32435732)
22. Barrett, P. J., Song, Y., Van Horn, W. D., Hustedt, E. J., Schafer, J. M., et al. (2012) The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 336, 1168-1171.
23. Nicholson, A. M., and, Ferreira, A., (2009) Increased membrane cholesterol might render mature hippocampal neurons more susceptible to beta-amyloid-induced calpain activation and tau toxicity. J. Neurosci. 29, 4640-4651.
24. Usui, K., Hulleman, J. D., Paulsson, J. F., Siegel, S. J., Powers, E. T., et al. (2009) Site-specific modification of Alzheimer's peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity. Proc. Natl. Acad. Sci. USA 106, 18563-18568.
25. Ferrera, P., Mercado-Gomez, O., Silva-Aguilar, M., Valverde, M., and, Arias, C., (2008) Cholesterol potentiates beta-amyloid-induced toxicity in human neuroblastoma cells: involvement of oxidative stress. Neurochem. Res. 33, 1509-1517.
26. Gamba, P., Testa, G., Sottero, B., Gargiulo, S., Poli, G., et al. (2012) The link between altered cholesterol metabolism and Alzheimer's disease. Ann. N Y Acad. Sci. 1259, 54-64.
27. Bjorkhem, I., Cedazo-Minguez, A., Leoni, V., and, Meaney, S., (2009) Oxysterols and neurodegenerative diseases. Mol. Aspects Med. 30, 171-179.
28. Vaya, J., and, Schipper, H. M., (2007) Oxysterols, cholesterol homeostasis, and Alzheimer disease. J. Neurochem. 102, 1727-1737. (Pubitemid 47329280)
29. Sparks, D. L., Scheff, S. W., Hunsaker, J. C. 3rd, Liu, H., Landers, T., et al. (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 88-94.
30. Refolo, L. M., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., et al. (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7, 321-331.
31. Shie, F. S., Jin, L. W., Cook, D. G., Leverenz, J. B., and, LeBoeuf, R. C., (2002) Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 13, 455-459. (Pubitemid 34293189)
32. Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., et al. (1997) Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17, 263-264.
33. Howland, D. S., Trusko, S. P., Savage, M. J., Reaume, A. G., Lang, D. M., et al. (1998) Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J. Biol. Chem. 273, 16576-16582. (Pubitemid 28311445)
34. Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., et al. (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 1977-1981. (Pubitemid 23069980)
35. Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., et al. (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 8098-8102. (Pubitemid 23260862)
36. Holtzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., et al. (1999) Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 103, R15-R21. (Pubitemid 29152639)
37. Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., et al. (2008) apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118, 4002-4013.
38. Poirier, J., (2000) Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann. N Y Acad. Sci. 924, 81-90. (Pubitemid 32050187)
39. Li, L., Cao, D., Garber, D. W., Kim, H., and, Fukuchi, K., (2003) Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am. J. Pathol. 163, 2155-2164. (Pubitemid 37466459)
40. Greenwood, C. E., and, Winocur, G., (1990) Learning and memory impairment in rats fed a high saturated fat diet. Behav. Neural Biol. 53, 74-87. (Pubitemid 20111364)
41. Winocur, G., and, Greenwood, C. E., (1999) The effects of high fat diets and environmental influences on cognitive performance in rats. Behav. Brain Res. 101, 153-161. (Pubitemid 29236360)
42. Winocur, G., and, Greenwood, C. E., (2005) Studies of the effects of high fat diets on cognitive function in a rat model. Neurobiol. Aging 26 (suppl 1), 46-49.
43. Granholm, A. C., Bimonte-Nelson, H. A., Moore, A. B., Nelson, M. E., Freeman, L. R., et al. (2008) Effects of a saturated fat and high cholesterol diet on memory and hippocampal morphology in the middle-aged rat. J. Alzheimers Dis. 14, 133-145. (Pubitemid 352040036)
44. Ullrich, C., Pirchl, M., and, Humpel, C., (2010) Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol. Cell. Neurosci. 45, 408-417.
45. Tong, X. K., Nicolakakis, N., Fernandes, P., Ongali, B., Brouillette, J., et al. (2009) Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol. Dis. 35, 406-414.
46. Kurata, T., Miyazaki, K., Kozuki, M., Panin, V. L., Morimoto, N., et al. (2011) Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res. 1371, 161-170.
47. Tong, X. K., Lecrux, C., and, Hamel, E., (2012) Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. J. Neurosci. 32, 4705-4715.
48. Kivipelto, M., Helkala, E. L., Laakso, M. P., Hanninen, T., Hallikainen, M., et al. (2002) Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann. Intern. Med. 137, 149-155. (Pubitemid 34827510)
49. Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., and, Yaffe, K., (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64, 277-281.
50. Solomon, A., Kareholt, I., Ngandu, T., Winblad, B., Nissinen, A., et al. (2007) Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 68, 751-756. (Pubitemid 46667900)
51. Reitz, C., Luchsinger, J., Tang, M. X., Manly, J., and, Mayeux, R., (2005) Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Neurology 64, 1378-1383. (Pubitemid 40570505)
52. Reitz, C., Tang, M. X., Luchsinger, J., and, Mayeux, R., (2004) Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch. Neurol. 61, 705-714. (Pubitemid 38637688)
53. Mielke, M. M., Zandi, P. P., Sjogren, M., Gustafson, D., Ostling, S., et al. (2005) High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 64, 1689-1695. (Pubitemid 40695799)
54. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S., and, Drachman, D. A., (2000) Statins and the risk of dementia. Lancet 356, 1627-1631.
55. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G., and, Siegel, G., (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439-1443.
56. Haag, M. D., Hofman, A., Koudstaal, P. J., Stricker, B. H., and, Breteler, M. M., (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry 80, 13-17.
57. Yaffe, K., Barrett-Connor, E., Lin, F., and, Grady, D., (2002) Serum lipoprotein levels, statin use, and cognitive function in older women. Arch. Neurol. 59, 378-384. (Pubitemid 34208144)
58. Zandi, P. P., Sparks, D. L., Khachaturian, A. S., Tschanz, J., Norton, M., et al. (2005) Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch. Gen. Psychiatry 62, 217-224. (Pubitemid 40189139)
59. Rea, T. D., Breitner, J. C., Psaty, B. M., Fitzpatrick, A. L., Lopez, O. L., et al. (2005) Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch. Neurol. 62, 1047-1051. (Pubitemid 41043724)
60. Arvanitakis, Z., Schneider, J. A., Wilson, R. S., Bienias, J. L., Kelly, J. F., et al. (2008) Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70, 1795-1802. (Pubitemid 351653958)
61. Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623-1630. (Pubitemid 35379733)
62. Heart Protection Study Collaborative Group.(2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22.
63. Sparks, D. L., Sabbagh, M. N., Connor, D. J., Lopez, J., Launer, L. J., et al. (2005) Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch. Neurol. 62, 753-757. (Pubitemid 40656090)
64. Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., et al. (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74, 956-964.
65. Wolozin, B., (2012) Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design. Alzheimers Res. Ther. 4, 3.